SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


[x]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                   For the quarterly period ended July 31, 1998

                                       OR

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

            For the transition period from              to
                                          --------------   ------------------

                         Commission file number 2-86360



                                INFORMEDICS, INC.
        (Exact name of small business issuer as specified in its charter)

                  Oregon                                 93-0750571
          (State of incorporation)         (I.R.S. Employer Identification No.)



             4000 Kruse Way Place, Bldg 3, Suite 300, Lake Oswego, OR 97035
                        (Address  of  principal  executive offices)

                    Issuer's telephone number: (503) 697-3000

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the Securities  Exchange Act of 1934 during the preceding
12 months (or for such shorter  period that the issuer was required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days. Yes X No

Number of shares of Informedics, Inc. $.01 par value common stock outstanding as
of August 31, 1998: 2,674,510.


<PAGE>



                                INFORMEDICS, INC.


                         Part I - Financial Information




         The information included herein is unaudited. However, such information
reflects all adjustments  (consisting solely of normal,  recurring  adjustments)
which are, in the opinion of management,  necessary for a fair  presentation  of
the  results of  operations  for the  interim  periods.  The  interim  financial
information  and notes thereto should be read in conjunction  with the Company's
latest  annual  report on Form 10-KSB.  The results of  operations  for the nine
months  ended  July 31,  1998 are not  necessarily  indicative  of results to be
expected for the entire year.


<PAGE>


<TABLE>
<CAPTION>

     INFORMEDICS, INC.
     STATEMENTS OF OPERATIONS

                                               Three Months Ended July 31,                   Nine Months Ended
July 31,
                                        ------------------------------------------    ----------------------------------------
                                               1998                     1997                 1998                    1997
<S>                                     <C>                    <C>                    <C>                   <C>   

                                        -------------------   --------------------    --------------------  ------------------

REVENUE:
Product Sales                                    $  43,659              $  99,707             $  252,495           $  523,717
Customer Service and Support                       601,079                622,438              1,890,111            1,959,358
                                        -------------------   --------------------   --------------------   ------------------

Total Revenue                                      644,738                722,145              2,142,606            2,483,075
                                        -------------------   --------------------    -------------------   ------------------

COSTS AND EXPENSES:
Cost of Products Sold                               29,628                 44,644                 81,932               98,305
Cost of Customer Service and Support
                                                   281,191                447,932                808,635            1,420,933
Selling & Administrative Expenses                  212,719                434,087                686,606            1,440,995
Depreciation & Amortization                         17,180                 99,095                 98,576              301,292
                                        -------------------   --------------------    -------------------   ------------------

Total Costs and Expenses                           540,718              1,025,758              1,675,749            3,261,525
                                        -------------------   --------------------    -------------------   ------------------

Operating Profit                                   104,020               (303,613)               466,857             (778,450)
(Loss)
                                        -------------------   --------------------    -------------------   ------------------

OTHER INCOME (EXPENSE):
Interest Expense                                       ---                   (237)                  (831)              (4,759)
Interest Income                                      7,751                  7,219                 29,670               26,918
Other Income                                             1                169,777                 24,752              179,876
                                        -------------------   --------------------    -------------------   ------------------

Total Other Income                                   7,752                176,759                 53,591              202,035
                                        -------------------   --------------------    -------------------   ------------------

PROFIT (LOSS) BEFORE
  INCOME TAXES                                     111,772               (126,854)               520,448             (576,415)

Income Tax Provision                                24,200                    ---                 65,400              688,025
                                        -------------------   --------------------    -------------------   ------------------

NET PROFIT (LOSS) AFTER
  INCOME                                         $  87,572           $   (814,879)             $ 455,048       $   (1,264,440)
TAXES
                                        ===================   ====================    ===================   ==================


BASIC AND DILUTED EARNINGS (LOSS)
PER SHARE                                          $  0.03              $   (0.31)                $ 0.17             $  (0.48)
                                        ===================   ====================    ===================   ==================
</TABLE>





See Notes to Financial Statements.


<PAGE>





<TABLE>
<CAPTION>

INFORMEDICS, INC.
BALANCE SHEETS

                                                                             July 31,           October 31,
ASSETS                                                                         1998                 1997
                                                                          ----------------   ----------------- 
<S>                                                                       <C>                <C>               

CURRENT ASSETS:

Cash                                                                           $  861,874           $  207,692
Accounts Receivable, Less Allowance  for Doubtful
   Accounts of $ 16,200 in 1998 and 1997                                          360,925              445,879
Inventories                                                                        16,186                3,304
Prepaid Expenses and Other Current Assets                                         108,683               55,267
Deferred Income Taxes                                                              43,200               90,500
Current Portion of Long-Term                                                       11,928               11,928
Receivable
                                                                          ----------------   ------------------

Total Current Assets                                                            1,402,796              814,570
                                                                          ----------------   ------------------

FIXED ASSETS:

Furniture and Fixtures                                                            114,171              135,505
Machinery and Equipment                                                           440,541              557,188
Leasehold Improvements                                                             29,583               27,258
Other Fixed Assets                                                                154,790              142,982
                                                                          ----------------   ------------------
                                                                                  739,085              862,933


Less Accumulated Depreciation and Amortization                                    667,690              737,093
                                                                          ----------------   ------------------

Total Fixed Assets                                                                 71,395              125,840
                                                                          ----------------   ------------------


OTHER ASSETS:

Long-Term Account Receivable                                                       21,868               30,814
Software Development Costs,
   Less Accumulated  Amortization of $ 825,312
   in 1998 and $ 787,791 in 1997                                                  183,108              169,540
Covenants Not to Compete,
   Less Accumulated Amortization of $ 494,012
   in 1998 and $ 493,862 in 1997                                                       33                  183
Deferred Income Taxes                                                             800,801              932,901
Tax Valuation Allowance                                                          (800,801)            (932,901)
Other                                                                              39,399               39,799
                                                                          ----------------   ------------------

Total Other Assets                                                                244,408              240,336
                                                                          ----------------   ------------------


TOTAL ASSETS                                                                 $  1,718,599         $  1,180,746
                                                                          ================   ==================
</TABLE>

See Notes to Financial Statements



<PAGE>
<TABLE>

<CAPTION>

INFORMEDICS, INC.
BALANCE SHEETS



                                                                            July 31,           October 31,
  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                              1998                 1997
                                                                        ------------------   -----------------


  CURRENT LIABILITIES:
<S>                                                                     <C>                   <C>            

  Accounts Payable and Accrued Expenses:
     Trade Accounts                                                            $   71,243           $  87,917
     Customer Deposits                                                             15,810              22,590
     Accrued Wages, Payroll Taxes and Employee Benefits                            60,054              86,362
     Other Accrued Liabilities                                                     15,391               9,445
  Deferred Revenue                                                              1,287,332           1,192,368
   Current Portion of Deferred Rent                                                 7,602              13,033
                                                                        ------------------  ------------------

  Total Current Liabilities                                                     1,457,432           1,411,715

  LONG-TERM OBLIGATIONS:

  Deferred Rent                                                                    13,033              17,378
  Deferred Tax Liability                                                           34,800              16,700
                                                                        ------------------  ------------------

  Total Current Liabilities and Long-Term Obligations                           1,505,265           1,445,793
                                                                        ------------------  ------------------

  STOCKHOLDERS' EQUITY (DEFICIT):

  Preferred Stock, $ .01 Par Value:
     Authorized 5,000,000 Shares;
     No Shares Outstanding                                                            ---                 ---
  Common Stock, $.01 Par Value:
     Authorized 15,000,000 Shares;
     Shares Outstanding:  2,674,510 in 1998 and
      2,654,708 in 1997                                                            26,745              26,546
  Capital in Excess of Par Value                                                1,941,176           1,918,042
  Note Receivable from Stockholder                                                (22,000)            (22,000)
  Accumulated Deficit                                                          (1,732,587)         (2,187,635)
                                                                        ------------------  ------------------


  Total Stockholders' Equity (Deficit)                                            213,334            (265,047)
                                                                        ------------------  ------------------


  TOTAL LIABILITIES AND STOCKHOLDERS'
    EQUITY (DEFICIT)                                                         $  1,718,599        $  1,180,746
                                                                        ==================  ==================
</TABLE>



  See Notes to Financial Statements.


<PAGE>



<TABLE>
<CAPTION>

INFORMEDICS, INC.

STATEMENTS OF CASH FLOWS
                                                                                Nine Months Ended July 31,

                                                                      ------------------------------------------
                                                                              1998                   1997
                                                                      ------------------------------------------

CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                                   <C>                    <C>           

  Net Income (Loss)                                                           $  455,048         $    (1,264,450)

ADJUSTMENTS TO RECONCILE NET INCOME
(LOSS) TO NET CASH AND CASH EQUIVALENTS PROVIDED BY OPERATING
ACTIVITIES:
 Depreciation and Amortization                                                   103,434                301,292
 Provision for Write-offs of Accounts Receivable                                     ---                 (5,712)
 Deferred Income Taxes                                                            65,400                606,813
 Gain on Sale of Assets                                                              ---               (106,990)
  Changes in Assets and Liabilities:
   Accounts Receivable                                                            84,954                309,700
   Income Taxes Receivable                                                                               81,212
   Inventories                                                                   (12,882)                 3,812
   Prepaid Expenses and Other Current Assets                                     (53,416)                (9,208)
   Accounts Payable and Accrued Expenses                                         (43,816)               (68,740)
   Notes Receivable                                                                8,946                359,197
   Deferred Revenue                                                               94,964                (21,900)
   Deferred Rent                                                                  (9,776)                (9,775)
                                                                      -------------------    -------------------
Net Cash and Cash Equivalents Provided by
   Operating Activities                                                          692,856                175,251
                                                                      -------------------    -------------------

INVESTING ACTIVITIES:
 Property Additions                                                              (18,952)               (40,019)
 Capitalized Software Development Costs                                          (51,088)               (86,884)
 Other                                                                             8,033                 12,589
                                                                      -------------------    -------------------
 Net Cash Used in Investing Activities                                           (62,007)              (114,314)
                                                                      -------------------    -------------------


FINANCING ACTIVITIES:
 Decrease in Revolving Line of Credit                                                ---               (125,000)
 Proceeds from Issuance of Common Stock                                           23,333                    ---
                                                                      -------------------    -------------------

 Net Cash Provided by (Used In) Financing Activities                              23,333               (125,000)
                                                                      -------------------    -------------------

NET INCREASE (DECREASE) IN CASH AND CASH
   EQUIVALENTS                                                                   654,182                (64,063)

CASH AND CASH EQUIVALENTS AT BEGINNING
   OF PERIOD                                                                     207,692                323,217
                                                                      -------------------    -------------------

CASH AND CASH EQUIVALENTS AT END
   OF PERIOD                                                                  $  861,874              $ 259,154
                                                                      ===================    ===================
</TABLE>
<PAGE>


<TABLE>
<CAPTION>

INFORMEDICS, INC.

STATEMENTS OF CASH FLOWS


                                                                        Nine Months Ended July 31,
                                                                --------------------------------------------
                                                                          1998                 1997
                                                                --------------------------------------------

<S>                                                                       <C>                  <C>          

Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                                                 $     832            $     4,759





</TABLE>


















See Notes to Financial Statements.




<PAGE>


INFORMEDICS, INC.

NOTES  TO FINANCIAL STATEMENTS


1.       SIGNIFICANT ACCOUNTING POLICIES

         Industry Segment
         ----------------

The  Company  derives  its  revenue  solely  from the  sales  and  servicing  of
microcomputer software and related hardware.

         Inventories
         -----------

Inventories are stated at the lower of cost or market.  Specific  identification
is used to determine the costs of hardware and software inventory.

         Fixed Assets
         ------------

Fixed assets are stated at cost, less accumulated depreciation and amortization.
The costs of fixed assets are depreciated  over the estimated  useful lives (two
to five years) of the assets using the straight-line method.
Leasehold improvements are amortized over the term of the lease (five years).

         Customer Service and Support Revenue
         ------------------------------------

Customer service and support revenue represents revenue earned from hardware and
software  maintenance  contracts,  training,  installation  of new systems,  and
general software support and programming  services provided to customers.  Under
renewable maintenance  contracts,  the Company provides, for a term of generally
not more than one year,  essentially all maintenance and repairs  resulting from
the normal and intended use of its  products.  Deferred  revenue on  maintenance
contracts  is  amortized  by the  straight-line  method  over  the  life  of the
contracts.

         Revenue Recognition
         -------------------

Revenue  from sales of software  and  hardware is  generally  recorded  when the
product is shipped. Revenue from custom software products, which are marketed to
customers  primarily under perpetual  license  arrangements,  is recorded at the
time the  product is  installed  and  accepted  by the  customer.  Revenue  from
services other than maintenance contracts is recognized as performed.

         Income Taxes
         ------------

Income taxes are accounted for using the methodology established by Statement of
Financial  Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes,"
which  requires an asset and a liability  approach to financial  accounting  and
reporting  for income  taxes.  Deferred  income tax assets and  liabilities  are
computed for differences between the financial statement and tax bases of assets
and liabilities that will result in taxable or deductible amounts in the future.
A valuation  allowance is  established  when  necessary  to reduce  deferred tax
assets to amounts  expected to be realized,  based on enacted tax laws and rates
applicable  to the  periods  in which the  differences  are  expected  to affect
taxable  income.  Income tax expense or benefit is the tax payable or refundable
for the  period,  plus or minus the change  during the  period in  deferred  tax
assets and liabilities.

<PAGE>






INFORMEDICS, INC.

NOTES  TO FINANCIAL STATEMENTS


         Software Development Costs
         --------------------------

Certain software  development costs are being capitalized and amortized over the
estimated economic life of the software, on a straight-line  method,  commencing
when each product or enhancement is available for general release.  Amortization
using the  straight-line  method for the nine-month  periods ended July 31, 1998
and 1997 was $ 37,521 and $ 121,040, respectively.

         Covenants Not to Compete
         ------------------------

Covenants not to compete are stated at the estimated value of the  consideration
given for the covenants  (including the present value of any future  payments to
be made under each agreement),  less accumulated amortization.  The costs of the
covenants are being amortized over four or seven years,  using the straight-line
method. Amortization for the nine-month periods ended July 31, 1998 and 1997 was
$ 150 and $ 7,718, respectively.

         Earnings  Per Share
         -------------------

         In February 1997, the Financial Accounting Standards Board (the "FASB")
issued SFAS No. 128,  "Earnings Per Share," which  established new standards for
computing and presenting  earnings per share ("EPS) to entities  having publicly
held  common  stock and  potential  common  stock.  SFAS No.  128  replaces  the
presentation  of  primary  EPS  with the dual  presentation  of a basic  EPS and
diluted EPS on the Company's  statements  of  operations.  The Company  computes
basic EPS by dividing net income by the weighted-average number of common shares
outstanding  and  diluted  EPS  by  dividing  net  income  by  the  sum  of  the
weighted-average  number of common shares outstanding and the dilutive effect of
stock options  outstanding  as if such options were  exercised or converted into
common shares. The Company's  computation of diluted EPS is essentially the same
as the  computation of primary EPS, which was presented prior to the adoption of
SFAS No. 128.

         There were no adjustments to net income in computing  diluted  earnings
per share for the  periods  ended July 31, 1998 and 1997.  The Company  uses the
treasury  stock  method to compute  the number of shares used in the diluted EPS
calculation  and, as such, in 1997 no shares are included for outstanding  stock
options as they would be  anitdilutive.  A  reconciliation  of the common shares
used in the  denominator  for  computing  basic and  diluted EPS for the periods
ended July 31, 1998 and 1997 is as follows:
<TABLE>
<CAPTION>

                                         Three Months Ended July 31,      Nine Months Ended July 31,
                                       --------------------------------  -----------------------------
                                            1998             1997            1998            1997
                                       ---------------  ---------------  -------------   -------------
<S>                                    <C>              <C>              <C>             <C>          
        Weighted-average shares
        outstanding, used in computing
        basic EPS                           2,671,638        2,650,307      2,671,638       2,650,307

        Effect of dilutive stock               28,258                          28,258
        options
                                       ---------------  ---------------  -------------   -------------

        Weighted-average  shares
        outstanding and the effect of
        dilutive stock options used in
        computing diluted EPS               2,699,896        2,650,307      2,699,896    2,650,307
                                       ===============  ===============  =============   =============
</TABLE>
<PAGE>







INFORMEDICS, INC.

NOTES  TO FINANCIAL STATEMENTS


Cash and Cash Equivalents
-------------------------

The Company  considers  cash on hand,  deposits  in bank and highly  liquid debt
instruments  purchased  with original  maturity  dates of six months or less, as
cash.

Accounting Changes
------------------

In October  1995,  the FASB  issued SFAS No. 123,  "Accounting  for  Stock-Based
Compensation."  This statement  establishes an alternative  method of accounting
that requires  recognizing  as expense the fair value of employee  stock options
and other  stock-based  awards at the grant  date.  SFAS No. 123 also allows the
continuation  of the current  accounting  treatment under which the Company does
not recognize compensation expense for the stock options it awards to employees.
Since the Company is electing  to retain its current  method,  it is required to
present pro forma disclosures in its annual financial  statements as if the fair
value based method had been applied.

In June 1997, the FASB issued SFAS No. 130,  "Reporting  Comprehensive  Income."
SFAS No. 130 establishes requirements for disclosure of comprehensive income and
becomes  effective  for the  Company's  fiscal  year ending  October  31,  1999.
Reclassification  of earlier  financial  statements for comparative  purposes is
required. The impact on the Company's financial statements is not material.

In June 1997,  the FASB issued SFAS No. 131,  "Disclosure  about  Segments of an
Enterprise  and Related  Information."  SFAS No. 131  establishes  standards for
disclosure about operating segments in annual financial  statements and selected
information in interim  financial  reports.  It also  establishes  standards for
related  disclosures  about products and services,  geographic  areas, and major
customers.  This  statement  supersedes  SFAS No. 14,  "Financial  Reporting for
Segments of a Business  Enterprise." The new standard becomes  effective for the
Company's  fiscal year ending  October 31, 1999,  and requires that  comparative
information  from earlier  years be restated to conform to the  requirements  of
this standard.


2.       CREDIT AGREEMENTS

         The Company has no credit line with a bank at this time.


3.       PENDING MERGER

On July 29,  1997,  the  Company  signed  a letter  of  intent  to merge  into a
subsidiary of Mediware Systems, Inc.  ("Mediware") of Melville,  NY. The Company
announced on December 19, 1997 the signing of an Agreement and Plan of Merger to
merge into the  Mediware  subsidiary  in a stock  exchange  whereby one share of
Mediware  stock would be exchanged for every 6.3 shares of the Company's  stock.
The merger is subject to the  approval of the  Company's  shareholders  which is
scheduled for September 23, 1998.

<PAGE>


INFORMEDICS, INC.

MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The following  discussion  includes certain  forward-looking  statements.  Those
statements involve a number of risks and uncertainties, which could cause actual
results  to  differ  materially  from  the  expectation  stated,  including  the
following: slower than expected sales of Informedics' products, deterioration of
business  conditions  generally or  specifically  in the  health-care  industry,
regulatory  changes  involving  health  care  or  medical  devices,  competitive
factors, price pressures and higher than expected turnover in key personnel.

Highlights

On July 29,  1997,  the  Company  signed  a letter  of  intent  to merge  into a
subsidiary of Mediware Systems, Inc.  ("Mediware") of Melville,  NY. The Company
announced on December 19, 1997 the signing of an Agreement and Plan of Merger to
merge into the  Mediware  subsidiary  in a stock  exchange  whereby one share of
Mediware  stock would be exchanged for every 6.3 shares of the Company's  stock.
The merger is subject to the  approval of the  Company's  shareholders  which is
scheduled for September 23, 1998.

The Company continued  improved  operating results for the third quarter and the
first nine months of fiscal 1998 when compared to the same periods in 1997.  The
Company  recorded a pre-tax  profit of  $111,772  for the third  quarter of 1998
compared to a third  quarter  loss of  $126,854 in 1997 and a pre-tax  profit of
$520,448  for the first nine months of 1998  compared to a loss of $576,415  for
the  same  period  in  1997.  The   improvement  was  primarily  the  result  of
cost-cutting  measures  fully  realized in fiscal 1998 offset in part by reduced
new system sales.

On July 1, 1998, the Company  received  510(k)  clearance from the Food and Drug
Administration ("FDA") to market its LifeLine blood bank data management system,
release 4.2. By receipt of the 510(k) clearance,  the Company  demonstrated that
its LifeLine product meets the safety and efficacy  requirements of the FDA. The
510(k) clearance is a major regulatory achievement for the Company.

The Company is currently  developing new software  releases for the LifeLine and
StarPath products, which address the Year 2000 issue, expanded bar code labeling
to  meet  anticipated  FDA  requirements,  and  customer-recommended  functional
improvements.  The Company has evaluated its anticipated  costs  associated with
these  releases  (expected  in the fourth  quarter of fiscal 1998 and the second
quarter of fiscal 1999, respectively),  including staffing levels,  distribution
costs, installation requirements and training. The Company's management believes
that it may incur as much as $300,000, including amounts spent to date, in costs
associated with these releases and other Year 2000 issues.

In 1997, the Company established a valuation reserve against its deferred income
taxes,  which  offset the income tax benefit for the first two quarters of 1997.
In the third  quarter of 1997,  this  reserve  was  increased  as the  Company's
management  determined that the benefit of the net operating loss  carryforwards
was not likely to be realized.  The Company was able to utilize some of this net
operating loss  carryforwards in the third quarter of 1998 to reduce the current
tax provision.

Results of Operations - Material Changes

New system  product sales were $56,048 lower in third quarter and $271,222 lower
for the first nine months of 1998 when compared to the same periods in 1997. The
decrease  for the nine  months  was due to fewer  sales  in all  product  lines,
including  IntraMed.net - $13,000;  StarPath - $29,765; and LifeLine - $123,785.
Discontinued  products  Entree' and  ClinicManager  accounted  for the remaining
product sales shortfall of $104,672.

Customer  service and support  revenue  was $21,359  lower in third  quarter and
$69,247  lower for the first  nine  months of 1998,  when  compared  to the same
periods in 1997. The 1997 results included one-time  programming service revenue
associated  with LifeLine and  ClinicManager  product  lines.  Hardware  support
revenue  decreased  40% in the first nine  months of 1998 when  compared  to the

<PAGE>

first  nine  months  of 1997,  but the  decline  was more  than  offset by a new
technical  support  service  which was intended to replace the hardware  support
service revenue.  The Company began marketing the new technical  support service
in the third quarter of 1997.

Hardware sales decreased $23,238 and $32,440 for the third quarter and the first
nine months of 1998, respectively,  as compared to the same periods in 1997. The
cost of products  sold in the third  quarter was $15,016 lower and $16,373 lower
in the first nine months of 1998 when compared to the same periods in 1997.

The cost of customer service and support decreased $166,741 and $612,298 for the
third  quarter and the first nine months of 1998,  respectively,  as compared to
the  same  periods  in  1997.  Likewise,  selling  and  administrative  expenses
decreased in 1998 when  compared to the same  periods in 1997.  These costs were
lower by $221,368 for the third quarter and $754,389 in the first nine months of
1998.  The cost  improvements  resulted  from a  reduction  in staff  and  other
overhead costs.  Management  anticipates that these costs will remain relatively
stable over the remainder of fiscal 1998.


Liquidity - Capital Resources

The  Company's  cash position grew from $207,692 on October 31, 1997 to $861,874
on July 31, 1998, as the Company added $692,856 of cash as a result of operating
activities,  used  $62,007 for  investing  activities,  and added  $23,333  from
financing  activities.  Based upon the  anticipation of continued steady product
sales and reduced  operating  expenses,  management  believes that the Company's
current cash position  will be  sufficient to fund its operating and  investment
activities for the remainder of fiscal 1998.

As a result  of the  operating  profit  in the first  nine  months of 1998,  the
Company  experienced an improvement of $542,509 in working capital.  The Company
had a negative  working  capital of $54,636 on July 31,  1998 as  compared  to a
negative $597,145 on October 31, 1997. Excluding the deferred revenue liability,
which is a liability for future services,  the Company's working capital on July
31, 1998 was $1,232,696 compared to $595,223 on October 31, 1997.

Capital  expenditures  for  property  additions  were  $18,952 in the first nine
months of 1998 compared to $40,019 in the first nine months of 1997.  Management
anticipates that capital  expenditures for property additions for the balance of
1998 will remain low.

Capitalized  software  development  costs were $51,088 and $86,884 for the first
nine  months  of  1998  and  1997,  respectively.  Management  anticipates  that
capitalized  software  development  costs for the  remainder of 1998 will remain
low.

The Company has no credit line with a bank at this time.


Year 2000 Compliance

The Year 2000 problem is the result of computer  programs that rely on two-digit
date codes,  instead of  four-digit  date  codes,  to  indicate  the year.  Such
computer programs,  which are unable to interpret the date code "00" as the year
2000, may not be able to perform computations and decision-making  functions and
could  cause  computer  systems to  malfunction.  Informedics  has  developed  a
multi-phase  program for Year 2000 information  systems compliance that consists
of (i) assessment,  remediation and testing of Informedics' software products to
make them Year 2000  compliant,  (ii)  assessment of the  corporate  systems and
operations of Informedics that could be affected by the Year 2000 problem,  (ii)
remediation of non-compliant systems and components, and (iv) testing of systems
and  components  following  remediation.  Informedics  has focused its Year 2000
review on three areas: (A)  Informedics'  products,  (B) information  technology
(IT) system applications, (C) non-IT systems, including telephone and voice mail
systems, and (D) relationships with third parties.

Informedics  has  determined  that certain  portions of its LifeLine  blood bank
software and StarPath pathology data management system software do not currently
meet the conditions for date protocol  compliance in the Year 2000.  Informedics
is currently  testing a new version of the LifeLine  product  which  Informedics
expects  will  meet  FDA  and  industry  standards  for  Year  2000  compliance.
Informedics  will begin  developing a new version of the StarPath product during

<PAGE>

the first  quarter of 1999.  Informedics  expects to release the new versions of
the  LifeLine  and  StarPath  products  in the fall of 1998 and  spring of 1999,
respectively.  All other current  Informedics'  software  products are Year 2000
compliant.  However,  prior versions of Informedics' products were not Year 2000
compliant.  Informedics'  customers who have support agreements with Informedics
will  receive  free  updated  Year 2000  compliant  software.  During the fourth
quarter of 1998 and the first quarter of 1999,  Informedics plans to contact all
customers  of  unsupported  versions of its  products to inform them of the Year
2000 issue.

Informedics has conducted an initial  assessment of the Year 2000 problem on its
IT systems.  Informedics  believes that its  enterprise-wide  software system is
Year 2000 compliant.  Such belief is based significantly on discussions with and
representations  by the vendor of such software.  Informedics has been, and will
continue to be, in contact  with such  vendor in order to obtain any  additional
revisions or upgrades  issued by the vendor to ensure that such  enterprise-wide
software remains Year 2000 compliant.  Informedics also is taking an independent
inventory of and assessing all  informational  systems that could be affected by
the Year 2000 problem.  Remediation of non-compliant  systems is being conducted
as the assessment phase nears completion.  Informedics expects to complete these
phases during the third quarter of 1998.

Informedics  also is in the process of conducting  an initial  assessment of the
Year 2000  problem on its non-IT  systems,  including  telephone  and voice mail
systems.  Informedics  expects to complete its initial  assessment of such areas
during  the  fourth  quarter  of  1998.   Following  such  initial   assessment,
Informedics   will  undertake  Year  2000   remediation  and  testing  of  these
applications.  Informedics cannot determine, at this time, the number or type of
non-IT  systems that will require  remediation;  however,  Informedics  does not
expect this area to pose material Year 2000 problems.

Finally,   Informedics  is  examining  its  relationships  with  third  parties,
including suppliers of hardware, network operating systems and utility programs,
whose  Year  2000   compliance   could  have  material  effect  on  Informedics.
Informedics considers these third party suppliers to pose the greatest Year 2000
risk to Informedics  because their failure to become Year 2000  compliant  could
result in Informedics' inability to obtain components in a timely manner, delays
or  cancellations  of  customer  orders or delay in payments  by  customers  for
products shipped. In addition,  conversions by third parties to become Year 2000
compliant might not be compatible with Informedics' systems. Any or all of these
events could have a material adverse effect on Informedics' business,  financial
condition and results of operations.

Informedics has requested  information from all of its significant  vendors with
respect to Year 2000 compliance status.  Informedics has received assurance that
all such suppliers are offering Year 2000 compliant products.  Informedics is in
the process of testing all such  products  with its new release of the  LifeLine
product.

Because of the assurances obtained and testing that is underway, Informedics has
not yet  developed a  contingency  plan to address the effects of the failure of
Informedics or any of its principal suppliers to become Year 2000 compliant, nor
does Informedics have a timetable for preparing such a plan. In what Informedics
believes to be the most likely  worst case  scenario,  Informedics  would change
hardware and operating system suppliers to Year 2000 compliant manufacturers.

Informedics' management estimates that Informedics may incur costs of as much as
$300,000  associated  with the  releases of the new versions of the LifeLine and
StarPath products. However, there can be no assurance that actual costs will not
exceed  management's  expectations,  that the new  versions of software  for the
LifeLine  and  StarPath  products  will timely  resolve  Informedics'  Year 2000
compliance  issues, or that the financial  condition or results of operations of
Informedics will not be substantially  adversely affected.  Informedics' current
estimates of the impact of the Year 2000 problem on its operations and financial
results do not  include  costs and time that may be  incurred as a result of any
vendors' or customers' failures to become Year 2000 compliant on a timely basis.

The foregoing beliefs and expectations are forward-looking statements within the
meaning of Section 27A of the  Securities  Act and  Section 21E of the  Exchange
Act, and are based in large part on certain statements and representations  made
by persons  outside  Informedics,  any of which  statements  or  representations
ultimately could prove to be inaccurate.



<PAGE>



                           Part II - Other Information




 Item 6.   Exhibits and Reports on Form 8-K

                    (a)  Exhibit.

                          27        Financial Data Schedule


Reports on Form 8-K

                           None


<PAGE>



                                   SIGNATURES



Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                   INFORMEDICS, INC.
                                   (Registrant)


Date:  September 15, 1998       By /s/ John Tortorici
       ------------------          ------------------------------------
                                   John Tortorici, Chairman, President,
                                   Chief Executive Officer and
                                   Chief Financial Officer









<PAGE>






                                   FORM 10-QSB

                                  Exhibit Index

Exhibit

27       Financial Data Schedule